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Abstract: Dry eye syndrome is a prevalent disease that affects visual acuity, activities of 
daily living, and quality of life. A number of contributory factors affect the severity of dry 
eye syndrome, including autoimmune disease, environmental surroundings, contact lens use, 
hormonal changes, anatomical features, chronic inflammation, infections, and iatrogenic 
  factors, such as medications or surgery. Symptoms may include intermittent or constant blurry 
vision, discomfort, burning, foreign body sensation, hyperemia, dryness, and photophobia. The 
severity of dry eye syndrome can range from very mild disease to extremely severe cases with 
vision-threatening consequences. A variety of dry eye treatment modalities exist to address the 
different causes, symptoms, and consequences of ocular surface disease, including artificial 
tears, lubricating gels, ophthalmic inserts, anti-inflammatory drops, and surgical procedures. 
In this paper, an assortment of literature pertaining to the treatment of dry eye syndrome, in 
particular hydroxypropyl cellulose ophthalmic inserts, is reviewed. These inserts can be used 
effectively as monotherapy, or in conjunction with other therapies, and should be considered 
in the treatment of dry eye syndrome.
Keywords: hydroxypropyl cellulose ophthalmic inserts, dry eye, punctal occlusion, ocular 
surface disease
Introduction
Dry eye syndrome is a multifactorial disease of the tears and ocular surface that results 
in symptoms of discomfort, burning, itching, foreign body sensation, dryness, pain, 
photophobia, hyperemia, visual disturbance, and tear film instability, with potential 
damage to the ocular surface.1 A number of contributory factors affect the degree 
of dry eye syndrome, including autoimmune disease, environmental   surroundings, 
contact lens use, hormonal changes, vitamin deficiencies, anatomical features, 
corneal dystrophies, chronic inflammation, infections, and iatrogenic factors, such 
as medications, radiation, and surgery.1,2 Dry eye can be classified into five types, 
ie, aqueous-deficient, mucodeficient, lipodeficient, epitheliopathic, and eyelid-eye 
incongruent.3 The International Dry Eye Workshop has classified dry eye etiology as 
either aqueous-deficient or evaporative.1 Aqueous deficiency is further classified as 
Sjogren-related or non-Sjogren-related dry eye, and evaporative is divided into intrin-
sic causes, including meibomian oil deficiency or lid disorders, and extrinsic causes, 
such as vitamin A deficiency, contact lens wear, or topical preservatives. Diagnosis 
of dry eye syndrome include subjective symptoms, as well as clinical signs, including 
punctate epithelial staining, tear film appearance and volume, tear film breakup time, 
tear film normalization test, and Schirmer tear test.1–3 It has been found that dry eye Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
588
Nguyen and Latkany
patients have reduced tear meniscus dynamics and smaller 
meniscus volume.4 Symptoms can be further classified by 
using one of a number of questionnaires, including the Ocular 
Surface Disease Index, a validated standardized instrument 
that measures disease severity and patient quality of life on 
a numerical scale in patients with dry eye syndrome. The 
severity of dry eye syndrome can range from very mild 
disease to extremely severe cases with vision-threatening 
consequences, such as ocular infections, perforations, 
endophthalmitis, and blindness. The severity of subjective 
symptoms does not necessarily correlate with the findings 
on clinical examination.5
Dry eye symptoms are one of the most common com-
plaints seen in clinical ophthalmology settings. Population-
based surveys have indicated that dry eye disease affects 
millions of people worldwide.6 A multitude of dry eye 
treatment modalities exist to address the different causes, 
symptoms, and consequences of ocular surface disease, 
including artificial tears, lubricating gels, anti-inflammatory 
or immunosuppressant drops, steroids, autologous serum or 
platelet-rich plasma drops, and punctal plugs. Less common 
treatments include hormonal therapy, vitamin A, botulinum 
toxin, acupuncture, and antiviral agents.7 There are also surgi-
cal procedures to improve the quality of severe ocular surface 
disease, including repair of lid abnormalities, lid tarsor-
rhaphy, submandibular gland transplantation, and canalicular 
occlusion, which can include canalicular excision, punctal 
tarsorrhaphy, punctal patch, or punctal cautery, all of which 
preserve the natural tears, which to date are irreplaceable and 
remain better than artificial tears.8 Studies have shown that 
after punctal occlusion, patients have symptomatic improve-
ment, as well as improvement in clinical signs of dry eye, 
tear film stability, and ocular surface retention.8–10
Hydroxypropyl cellulose ophthalmic inserts are another 
treatment available for moderate-to-severe dry eye   syndrome. 
The chemical name for hydroxypropyl cellulose is cellu-
lose, 2-hydroxypropyl ether. It is a tasteless, odorless, and 
physiologically inert substance, and is soluble in water below 
38°C. The ophthalmic inserts are sterile and translucent rods 
measuring 1.27 mm in diameter and 3.5 mm long. Each insert 
contains 5 mg of hydroxypropyl cellulose, with no preserva-
tives or any other ingredients. The medication is administered 
by placing a single insert into the inferior cul de sac of the 
eye beneath the base of the tarsus, not in opposition to the 
cornea, nor beneath the eyelid at the level of the tarsal plate.11 
Hydroxypropyl cellulose ophthalmic inserts act by stabiliz-
ing and thickening the tear film and prolonging tear film 
breakup time, as well as lubricating and protecting the eye. 
The inserts are indicated especially for patients who continue 
to have dry eye symptoms after an adequate trial of therapy 
with artificial tears.11 They are also indicated for patients 
with keratoconjunctivitis sicca, exposure keratitis, decreased 
corneal sensitivity, and recurrent corneal erosions.11 The only 
contraindication to using this medication is hypersensitivity 
to hydroxypropyl cellulose.11
Several studies have been performed to evaluate the 
efficacy of hydroxypropyl cellulose ophthalmic inserts. In 
one study, 418 patients were evaluated with questionnaires 
after four weeks of treatment on hydroxypropyl cellulose 
ophthalmic inserts.12 The patient questionnaires were com-
pleted prior to initiation of treatment, and again after four 
weeks of treatment to assess the difference in severity of 
symptoms, ability to perform activities of daily living, quality 
of life, and frequency of discomfort in various environmental 
conditions. All participating patients were required to have a 
diagnosis of dry eye syndrome in both eyes, and a history of 
intermittent or regular artificial tear use. The patients were 
subdivided into patients without comorbid conditions and 
five groups of patients with comorbid conditions, including 
contact lens wearers, patients with cataracts, patients with 
glaucoma, patients who have undergone cataract surgery, 
and patients who have undergone prior laser-assisted in situ 
keratomileusis. Patients were excluded if they have clinically 
significant blepharitis, meibomian gland dysfunction, lid 
margin or ocular inflammation, ocular infection, laser kera-
torefractive surgery within 12 months, or any other ocular 
surgery within three months. Patients were also screened for 
hydroxypropyl cellulose hypersensitivity. The patients were 
prohibited from starting any new dry eye therapy that they 
were not previously using throughout the trial. The results of 
the study demonstrated that both patients with and without 
comorbidities had statistically significant improvements in 
symptoms of discomfort, burning, dryness, grittiness, sting-
ing, and light sensitivity, as well as improvements in ability 
to perform activities of daily living and in quality of life. The 
three groups that showed the most improvement occurred 
in contact lens wearers, patients with prior cataract surgery, 
and patients with prior laser-assisted in situ keratomileusis. 
Although patients with only glaucoma or cataracts did not 
show as much improvement as the three previously men-
tioned groups, they still showed a statistically significant 
improvement.
A prospective study was published in which enrolled 
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of artificial tear use completed questionnaires at two 
visits, ie, at the beginning and at the end of a four-week 
  registry.13 Most of the patients were women and over the 
age of 50 years, and age did correlate with a difference 
in response. There was more than 25% improvement in 
severity of discomfort, burning, dryness, grittiness, sting-
ing, and sensitivity to light. Fifty-eight percent of the 
patients noted a statistically significant improvement in at 
least one symptom of the Ocular Surface Disease Index. 
Another study revealed similar findings, in which mean 
Ocular Surface Disease Index total scores improved by 
21.3%.14 The study reported fairly good compliance, and 
the main adverse event that led to discontinuation was 
blurred vision.
A retrospective case series study was performed to deter-
mine whether patients experienced improvement in dry eye 
symptoms after use of hydroxypropyl cellulose ophthalmic 
inserts.15 Data from the study were obtained from medical 
records of patients who has been given a prescription for 
hydroxypropyl cellulose ophthalmic inserts within two 
years prior to the study. This included patients who were 
newly started on the inserts, as well as patients who were 
already being treated with the inserts prior to the two years. 
The patients were predominantly female and over the age 
of 60 years. Of the 80 participating patients, 73 were still 
currently using the insert, and most were using the inserts at 
least once a day (93.2%). Some of the patients were using 
concomitant dry eye therapies, including topical antibiotics, 
artificial tears, and immunomodulators. The study reported 
a very low rate of adverse effects, which included blurred 
vision and foreign body sensation, and was only 2.5%. The 
duration of therapy ranged from 10 days to over 26 years. 
The median duration of therapy with the insert was 5.3 years, 
and almost two-thirds of the patients continued to use the 
insert for more than two years. The long duration of use 
suggests that the medication is relatively safe, well tolerated, 
effective for long-term therapy, and successful in patients 
over the age of 60 years.
A more recent study evaluated whether subjective patient-
reported improvement in symptoms after treatment with 
hydroxypropyl cellulose ophthalmic inserts correlated with 
physician assessment of clinical signs.16 The study reported 
that over 75% of patients had an overall improvement in their 
symptoms after being treated for one month with hydroxy-
propyl cellulose ophthalmic inserts. It also reported that 
patient-reported improvements strongly correlated with and 
significantly predicted physician assessment of the condition, 
effectiveness of therapy, and willingness to use the inserts 
as adjunctive therapy.
A crossover study was performed in 22 patients with 
rheumatoid arthritis and moderate-to-severe kerato-
conjunctivits sicca, who were treated with slow-release 
artificial tear inserts.17 Half of the participants used one insert 
daily, and the other group used methylcellulose artificial 
tears four times a day. After two weeks, the participants were 
evaluated for subjective symptomatic changes and clinical 
staining. Thereafter, the participants all used artificial tears 
for one week. The groups were then switched to the opposite 
treatment and reassessed after a further two weeks. The study 
reported that 86% of the patients approved of the insert as 
therapy, and 64% of the patients preferred the inserts to the 
artificial tears. These results are similar to those of another 
study reporting that 75% of their patients with keratitis sicca 
preferred the slow-release artificial tear inserts as the main 
form of treatment.18 Despite having varying degrees of hand 
deformities and loss of dexterity because of rheumatoid 
arthritis, most patients reported no difficulty with insertion 
of the medication.
Safety
Although rheumatoid arthritis is not a contraindication to 
use of hydroxypropyl cellulose ophthalmic inserts, there are 
some drawbacks to the medication. Educating patients how 
to administer the inserts can be time-consuming and dif-
ficult. Possible side effects were reported in approximately 
2.5% of patients, and these side effects included blurring of 
vision, foreign body sensation, ocular irritation or hyperemia, 
hypersensitivity, photophobia, eyelid edema, and caking 
or drying of viscous material on eyelashes.12,15 One study 
reported a corneal abrasion, but this was reportedly unrelated 
to ophthalmic insert usage.12 There are no reports of worsen-
ing of vision or dry eye symptoms, and most reported side 
effects have been mild and had no long-term or permanent 
adverse outcomes.
The most common reported side effect of hydroxypropyl 
cellulose ophthalmic inserts is blurred vision. The tear film 
is an important optical component that contributes to visual 
function. It has been reported that irregularities in the tear 
film can cause optical aberrations, fundus image degradation, 
decrease in contrast sensitivity, neural sharpness, and retinal 
vessel contrast.19,20 It has been observed that, as time increases 
after a blink, wavefront contours become more irregular and 
numerous, reflecting an increase in corneal wavefront aber-
rations, leading to perceptible degradation in vision.21,22 The Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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effect of improving the tear film may be used as a diagnostic 
tool in detecting ocular surface disease in symptomatic 
and asymptomatic patients.23 While dry eye patients have 
blurred vision due to irregular corneal surface, the cause of 
blurred vision after insert application is most likely due to 
the viscous nature of the medication, not an insufficient tear 
film. In addition, although blurred vision was one of the 
most common side effects, most patients reported significant 
improvements in their ability to perform daily activities and 
visual tasks, particularly activities such as reading, watching 
television, working on the computer, and driving at night.12 
This suggests that the blurred vision was not severe or visu-
ally impairing, and did not reduce quality of life. Blurred 
vision was also transient, and there were no reported cases 
of long-term decrease in vision.
Conclusion
In conclusion, there are various treatment modalities for dry 
eye syndrome available to eye care professionals, which 
can be used as monotherapy or in combination. There is 
evidence to suggest that with proper use and adequate patient 
education, hydroxypropyl cellulose ophthalmic inserts are an 
effective and safe treatment choice for dry eye syndrome. 
Most patients showed significant improvement in ocular 
symptoms and clinical signs, and many patients continued 
using hydroxypropyl cellulose ophthalmic inserts for several 
years alone or in conjunction with other dry eye therapies. 
There was no significant worsening in symptoms or any 
major long-term side effects of the medication. The inserts 
may be particularly helpful in patients who cannot tolerate 
preservatives or immunosuppressant drops, do not want to 
instill multiple artificial tears throughout the day, or still have 
an insufficient tear film despite other therapies. However, it 
is worth noting that several of the studies excluded patients 
with meibomian gland disease or blepharitis. It remains to 
be seen if the inserts help patients with evaporative aqueous 
tear loss due to meibomian gland dysfunction or blepharitis. 
One would think that both of these disease groups would 
benefit from using the inserts because there is often overlap 
of patients who also have dry eye syndrome. Nonetheless, 
hydroxypropyl cellulose ophthalmic inserts can be used 
effectively as monotherapy, or in conjunction with other 
therapies, and should be considered in the treatment of dry 
eye syndrome.
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